A study in the Journal of the American Medical Association showed that the earlier a stroke patient receives clot-dissolving drugs, the better the outcome. Researchers looked at data from more than 58,000 ischemic stroke patients. Patients treated with tissue plasminogen activators within 90 minutes of symptom onset had a 26% lower risk of death and 28% reduced risk of intracranial hemorrhage than those treated within 181 to 270 minutes, for example.

Related Summaries